Shawn Hayden, MD
Internal Medicine · Memphis, TNNPI 1609835909
Payments from drug & device makers
Across 484 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Novo Nordisk$919
- Merck$882
- Theratechnologies Inc.$742
- Lilly USA, LLC$692
- plus $3K from 27 others
What the payments were for
- Food & beverage$9,728100%
- Education$480%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 81 | $2,092 |
| Viiv Healthcare Company | 60 | $1,009 |
| Novo Nordisk | 47 | $919 |
| Merck | 45 | $882 |
| Theratechnologies Inc. | 35 | $742 |
| Lilly USA, LLC | 43 | $692 |
| AstraZeneca | 36 | $606 |
| GSK | 23 | $433 |
| Bayer | 19 | $388 |
| Johnson & Johnson(2 entities) | 11 | $284 |
| AbbVie | 15 | $266 |
| Pfizer | 12 | $227 |
| Astellas Pharma US Inc | 5 | $151 |
| Amgen | 2 | $142 |
| Sanofi-aventis U.S. LLC | 8 | $120 |
| Abbott | 6 | $119 |
| Boehringer Ingelheim | 5 | $95 |
| Boston Scientific | 1 | $83 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $82 |
| Exact Sciences | 5 | $76 |
| Kowa Pharmaceuticals America, Inc. | 5 | $74 |
| Amarin Pharma, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Edwards Lifesciences | 1 | $31 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Vyera Pharmaceuticals, LLC | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,777 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 66 | $273,277 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 29 | $141,144 |
| EliquisApixaban | 149 | $127,756 |
| OzempicSemaglutide | 91 | $96,975 |
| DescovyEmtricitabine/Tenofov Alafenam | 37 | $84,523 |
| RybelsusSemaglutide | 39 | $70,430 |
| XareltoRivaroxaban | 69 | $69,775 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,213 |
| MounjaroTirzepatide | 48 | $50,509 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $38,206 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $37,880 |
| JanuviaSitagliptin Phosphate | 38 | $36,914 |
| FarxigaDapagliflozin Propanediol | 34 | $32,762 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $25,276 |
| PifeltroDoravirine | 12 | $24,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $2,092 | $357,800103 claims |
| Novo NordiskOzempic, Rybelsus | $919 | $167,406130 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay | $1,009 | $164,95040 claims |
| PfizerEliquis | $227 | $127,756149 claims |
| MerckJanuvia, Pifeltro, Dulera, Janumet Xr | $882 | $77,06084 claims |
| Johnson & JohnsonXarelto, Invokana | $284 | $76,76681 claims |
| Lilly USA, LLCMounjaro, Trulicity | $692 | $74,46765 claims |
| GSKTrelegy Ellipta | $433 | $37,88046 claims |
| AstraZenecaFarxiga | $606 | $32,76234 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $120 | $25,27637 claims |
| Boehringer IngelheimJardiance | $95 | $21,92013 claims |
| AbbVieSavella | $266 | $6,09312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Phillip NorthcrossMemphis$39K
- Lawrence WhitlockMemphis$36K
- Angela WatsonMemphis$32K
- William CushmanMemphis$24K
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.